

NEWS RELEASE

Grant of Stock Options

December 21, 2011

Trading Symbol: TSX-V: APC

Advanced Proteome Therapeutics Corporation (the “Corporation” or “APC”) announces that it has granted stock options to directors, officers and consultants to purchase an aggregate of 1,230,000 common shares in the capital of the Corporation, exercisable at a price of \$0.10 per share for ten years, subject to regulatory approval. The options are granted in accordance with the Corporation’s Stock Option Plan and the vesting provisions contained therein.

About APC

APC’s primary corporate mission is to advance chemical methods which afford advantages to site-specifically modify proteins to impact critical unmet medical needs. Site-specific modifications represent the gold standard underlying redevelopment technologies to produce new, improved versions of therapeutic proteins and the ultimate regulatory standard for the production of new protein therapeutics. APC is applying its chemical platform “Swift Linkage Multivalent Technology” to specifically target cells which reveal phosphatidylserine, a distinctive feature in multiple diseases with elevated sites of apoptosis and necrosis as well as certain cancers. The combination of the chemical platform focusing on site specific modifications of protein products and their site-specific delivery to cellular targets has broad therapeutic potential.

ON BEHALF OF THE BOARD

Alexander (Allen) Krantz
President and Chief Executive Officer

FOR FURTHER INFORMATION PLEASE CONTACT:

Advanced Proteome Therapeutics Inc.
Tel: (800) APT 1169

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.